-Secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease

Author： Preece P.   Virley D.J.   Costandi M.   Coombes R.   Moss S.J.   Mudge A.W.   Jazin E.   Cairns N.J.  

Publisher： Elsevier

ISSN： 0169-328X

Source： Molecular Brain Research, Vol.116, Iss.1, 2003-08, pp. : 155-158

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

BACE1: The β-Secretase Enzyme in Alzheimer's Disease

By Vassar Robert  

Journal of Molecular Neuroscience, Vol. 23, Iss. 1-2, 2004-04 ,pp. : 105-114

Humana Press, Inc

Access to resources Recommend Favorite

Reduced GSK-3β mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients

By Kozlovsky N.   Shanon-Weickert C.   Tomaskovic-Crook E.   Kleinman J. E.   Belmaker R. H.   Agam G.  

Journal of Neural Transmission, Vol. 111, Iss. 12, 2004-12 ,pp. : 1583-1592

Springer Publishing Company

Access to resources Recommend Favorite

The β-secretase, BACE: A prime drug target for Alzheimer’s disease

By Vassar Robert  

Journal of Molecular Neuroscience, Vol. 17, Iss. 2, 2001-10 ,pp. : 157-170

Humana Press, Inc

Access to resources Recommend Favorite

Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer’s disease β-secretase (BACE-1)

By Blasko I.   Beer R.   Bigl M.   Apelt J.   Franz G.   Rudzki D.   Ransmayr G.   Kampfl A.   Schliebs R.  

Journal of Neural Transmission, Vol. 111, Iss. 4, 2004-04 ,pp. : 523-536

Springer Publishing Company

Access to resources Recommend Favorite

PP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus

By Vogelsberg-Ragaglia V.   Schuck T.   Trojanowski J.Q.   Lee V.M.-Y.  

Experimental Neurology, Vol. 168, Iss. 2, 2001-04 ,pp. : 402-412

Elsevier

Access to resources Recommend Favorite